MTX-531 is an oral drug that inhibits EGFR (with an IC 50 of 14.7 nM) and PI3K (with IC 50 values of 6.4, 233, 8.3, and 1.1 nM for PI3Kα , PI3Kβ , PI3Kγ , and PI3Kδ respectively), and it has anti-tumor effects. MTX-531 also acts as a weak agonist of PPARγ , with an IC 50 of 2.5 µM, helping to alleviate hyperglycemia induced by PI3K inhibitors.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.